

Yair Herishanu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6158783/publications.pdf>

Version: 2024-02-01

104
papers

2,963
citations

331259

21
h-index

189595

50
g-index

106
all docs

106
docs citations

106
times ranked

4619
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients â€” a matched control multicenter cohort study. <i>Haematologica</i> , 2022, 107, 1111-1118.	1.7	25
2	Characteristics and recognition of early infections in patients treated with commercial antiâ€”CD19 CARâ€”T cells. <i>European Journal of Haematology</i> , 2022, 108, 52-60.	1.1	10
3	Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 148-151.	2.5	15
4	Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVIDâ€”19 infection. <i>Journal of Medical Virology</i> , 2022, 94, 1241-1245.	2.5	22
5	Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. <i>Blood</i> , 2022, 139, 678-685.	0.6	96
6	BNT162b2 mRNA COVIDâ€”19 vaccine booster induces seroconversion in patients with Bâ€”cell nonâ€”Hodgkin lymphoma who failed to respond to two prior vaccine doses. <i>British Journal of Haematology</i> , 2022, 196, 1329-1333.	1.2	13
7	Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma?. <i>Cancers</i> , 2022, 14, 750.	1.7	5
8	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	3.3	72
9	Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCLâ€” a matched cohort analysis. <i>Annals of Hematology</i> , 2022, 101, 755.	0.8	1
10	The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients. <i>Clinical Microbiology and Infection</i> , 2022, 28, 735.e5-735.e8.	2.8	12
11	REGENâ€”COV antibody combination in patients with lymphoproliferative malignancies and SARSâ€”CoVâ€”2 infection. <i>EJHaem</i> , 2022, 3, 471-474.	0.4	4
12	COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge. <i>Cancer Cell</i> , 2022, 40, 578-580.	7.7	12
13	Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. <i>Journal of Clinical Oncology</i> , 2022, 40, 7539-7539.	0.8	17
14	Favezelimab (antiâ€”LAG-3) plus pembrolizumab in patients with antiâ€”PD-1â€”naïve relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study. <i>Journal of Clinical Oncology</i> , 2022, 40, 7516-7516.	0.8	2
15	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	3.3	17
16	Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 118-124.	0.6	23
17	Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel. <i>Leukemia and Lymphoma</i> , 2021, 62, 1136-1145.	0.6	5
18	Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2021, 192, e1-e4.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	1.1	5
20	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	2.0	10
21	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3165-3173.	0.6	539
22	Lower Patient Anxiety and Unchanged Levels of Adherence to Hemato-Oncologic Treatment in Response to New Measures to Reduce Hospital Exposure Risk to COVID-19. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 945-952.	0.8	2
23	Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3540-3549.	3.3	33
24	<i>TP53</i> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	2.0	8
25	Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells. <i>Frontiers in Oncology</i> , 2021, 11, 646971.	1.3	7
26	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	2.0	3
27	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021, 35, 3059-3072.	3.3	40
28	Feasibility of CD24/CD11b as a Screening Test for Hematological Malignancies. <i>Journal of Personalized Medicine</i> , 2021, 11, 724.	1.1	4
29	COVID-19 and Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 328-333.	1.0	7
30	Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2021, 195, 186-193.	1.2	65
31	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	3.3	57
32	Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study. <i>Blood</i> , 2021, 138, 3727-3727.	0.6	2
33	Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. <i>Blood</i> , 2021, 138, 2641-2641.	0.6	0
34	The Outcome of CLL Patients According to IGHV Mutational Status: An Israeli Perspective. <i>Blood</i> , 2021, 138, 4686-4686.	0.6	0
35	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	0.6	1
36	Bone marrow dendritic cells support the survival of chronic lymphocytic leukemia cells in a CD84 dependent manner. <i>Oncogene</i> , 2020, 39, 1997-2008.	2.6	2

#	ARTICLE	IF	CITATIONS
37	Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs. <i>Journal of the American Chemical Society</i> , 2020, 142, 11734-11742.	6.6	122
38	The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants. <i>British Journal of Haematology</i> , 2020, 189, e31-e33.	1.2	9
39	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
40	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	2.0	12
41	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1278-1291.	6.3	393
42	Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20011-e20011.	0.8	0
43	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
44	A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain. <i>European Journal of Haematology</i> , 2019, 103, 335-341.	1.1	5
45	Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. <i>Mycoses</i> , 2019, 62, 1140-1147.	1.8	57
46	Primary peg-filgrastim prophylaxis versus filgrastim given on demand for neutropenia during therapy with cladribine for hairy cell leukemia. <i>Leukemia Research</i> , 2019, 82, 24-28.	0.4	2
47	Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study. <i>American Journal of Hematology</i> , 2019, 94, 992-1001.	2.0	14
48	Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience. <i>Hematological Oncology</i> , 2019, 37, 185-192.	0.8	7
49	Wide-range effects of the MALT-1 inhibitor Mi-2 in CLL cells results in apoptosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 817-820.	0.6	5
50	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018, 32, 1869-1873.	3.3	8
51	Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study. <i>Annals of Hematology</i> , 2018, 97, 459-466.	0.8	1
52	A phase II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach. <i>British Journal of Haematology</i> , 2018, 182, 125-128.	1.2	15
53	Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival. <i>Hematological Oncology</i> , 2018, 36, 128-135.	0.8	6
54	Treatment and prognosis of stage I follicular lymphoma in the modern era – does PET matter?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1163-1171.	0.6	3

#	ARTICLE	IF	CITATIONS
55	CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines. <i>Leukemia and Lymphoma</i> , 2018, 59, 1878-1883.	0.6	1
56	Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel. <i>Anticancer Research</i> , 2018, 38, 6423-6429.	0.5	13
57	Elevated serum BDNF levels are associated with favorable outcome in CLL patients: Possible link to CXCR4 downregulation. <i>Experimental Hematology</i> , 2018, 63, 17-21.e1.	0.2	8
58	Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials. <i>European Journal of Haematology</i> , 2018, 101, 399-406.	1.1	5
59	Predictive value of the <scp>CLL</scp>â€‹<scp>IPI</scp> in <scp>CLL</scp> patients receiving chemo-immunotherapy as first-line treatment. <i>European Journal of Haematology</i> , 2018, 101, 703-706.	1.1	8
60	Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity. <i>Leukemia Research</i> , 2018, 71, 1-5.	0.4	14
61	Severe hepatitis B virus reactivation related to ibrutinib monotherapy. <i>Annals of Hematology</i> , 2017, 96, 689-690.	0.8	35
62	Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, 874-882.	1.7	67
63	Familial chronic lymphocytic leukemia in Israel: A disproportionate distribution among Ashkenazi Jews. <i>European Journal of Haematology</i> , 2017, 99, 51-55.	1.1	0
64	Fragility of sub-cellular structures in chronic lymphocytic leukemia. <i>International Journal of Hematology</i> , 2017, 105, 707-708.	0.7	2
65	CD74 is a novel transcription regulator. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 562-567.	3.3	113
66	Increased serum C-reactive protein levels are associated with shorter survival and development of second cancers in chronic lymphocytic leukemia. <i>Annals of Medicine</i> , 2017, 49, 75-82.	1.5	17
67	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016, 60, 154-165.	1.3	22
68	Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)â€‹ViLen-01 protocol. <i>Annals of Hematology</i> , 2016, 95, 1811-1818.	0.8	5
69	Measurement of lymphocyte aggregation by flow cytometryâ€‹physiological implications in chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 257-266.	0.7	10
70	Reduced-dose ICE chemotherapyâ€‹rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1633-1639.	0.6	12
71	High Peripheral Blood Circulating BDNF Levels Are Associated with Good Prognosis in CLL Patients; A CXCR-4 Dependent Effect?. <i>Blood</i> , 2016, 128, 5562-5562.	0.6	0
72	Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. <i>Haematologica</i> , 2015, 100, 662-669.	1.7	19

#	ARTICLE	IF	CITATIONS
73	Higher Infection Rate After 7- Compared With 5-Day Cycle of Azacitidine in Patients With Higher-Risk Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e95-e99.	0.2	18
74	Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli <scp>CLL</scp> Study Group. <i>European Journal of Haematology</i> , 2014, 93, 29-33.	1.1	25
75	Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrations. <i>Leukemia Research</i> , 2014, 38, 484-489.	0.4	8
76	Cancer Registries Often Underestimate the True Incidence of CLL. <i>Blood</i> , 2014, 124, 5646-5646.	0.6	1
77	Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience. <i>Blood</i> , 2014, 124, 5659-5659.	0.6	1
78	Biology of Chronic Lymphocytic Leukemia in Different Microenvironments. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 173-206.	0.9	86
79	B-cell receptor signaling in chronic lymphocytic leukemia leans on Lyn. <i>Leukemia and Lymphoma</i> , 2013, 54, 1125-1126.	0.6	3
80	Absolute monocyte count trichotomizes chronic lymphocytic leukemia into high risk patients with immune dysregulation, disease progression and poor survival. <i>Leukemia Research</i> , 2013, 37, 1222-1228.	0.4	21
81	Divergence in CD19-Mediated Signaling Unfolds Intraclonal Diversity in Chronic Lymphocytic Leukemia, Which Correlates with Disease Progression. <i>Journal of Immunology</i> , 2013, 190, 784-793.	0.4	8
82	Richter's Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors. <i>Blood</i> , 2013, 122, 5281-5281.	0.6	0
83	Absolute Monocyte Count Trichotomizes Chronic Lymphocytic Leukemia Into High Risk Patients With Immune Dysregulation, Disease Progression and Poor Survival. <i>Blood</i> , 2013, 122, 4724-4724.	0.6	0
84	JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts. <i>Israel Medical Association Journal</i> , 2013, 15, 698-700.	0.1	4
85	Complete Spontaneous Regression of Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, e254-e256.	0.8	6
86	Acute myeloid leukemia with 11q23/<scp>MLL</scp> rearrangement after <scp>FCR</scp>™ regimen for chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2012, 89, 430-431.	1.1	2
87	Prognostic Significance of the FISH Panel for Patients with Multiple Myeloma. <i>Blood</i> , 2012, 120, 5001-5001.	0.6	1
88	Divergence in CD19-Mediated Signaling Unfolds Intra-Clonal Diversity in Chronic Lymphocytic Leukemia Which Correlates with Disease Progression. <i>Blood</i> , 2012, 120, 4570-4570.	0.6	0
89	Increased CD39 Expression on CD4+ T-Lymphocytes Has Clinical and Prognostic Significance in Chronic Lymphocytic Leukemia,. <i>Blood</i> , 2011, 118, 3895-3895.	0.6	0
90	Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,. <i>Blood</i> , 2011, 118, 3811-3811.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Intra-Clonal Diversity Identified by CD19-Mediated Signaling Correlates with Disease Progression In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 3577-3577.	0.6	0
92	Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.. <i>Blood</i> , 2010, 116, 4620-4620.	0.6	0
93	Early mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2007, 79, 150-154.	1.1	23
94	Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. <i>European Journal of Haematology</i> , 2007, 79, 205-209.	1.1	116
95	Fluorine-18 Fluorodeoxyglucose PET/CT Patterns of Extranodal Involvement in Patients with Non-Hodgkin Lymphoma and Hodgkin's Disease. <i>PET Clinics</i> , 2006, 1, 251-263.	1.5	6
96	Fatal Interstitial Pneumonitis Related to Rituximab-Containing Regimen. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 407-409.	1.4	43
97	Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. <i>European Journal of Haematology</i> , 2006, 76, 516-520.	1.1	137
98	Detection of ZAP70 Negative B-CLL Patients Using the Beckman Coulters Positional Parameter Technology and RPD (Research Population Data) Analysis.. <i>Blood</i> , 2006, 108, 4934-4934.	0.6	0
99	Chronic lymphocytic leukemia: A review of some new aspects of the biology, factors influencing prognosis and therapeutic options. <i>Transfusion and Apheresis Science</i> , 2005, 32, 85-97.	0.5	18
100	Rituximab Retreatment in B-Cell Non-Hodgkins Lymphoma Patients.. <i>Blood</i> , 2005, 106, 2455-2455.	0.6	1
101	Enoxaparin can be Used Safely in Patients with Severe Thrombocytopenia due to Intensive Chemotherapy Regimens. <i>Leukemia and Lymphoma</i> , 2004, 45, 1407-1411.	0.6	58
102	Quantitation of Zap-70 Expression in B-CLL Cells Employing a Novel Flow Cytometry Analysis Method.. <i>Blood</i> , 2004, 104, 4785-4785.	0.6	0
103	Autoimmune Thrombocytopenia in Chronic Myeloid Leukemia Treated with Interferon-alpha: Differential Diagnosis and Possible Pathogenesis. <i>Leukemia and Lymphoma</i> , 2003, 44, 2103-2108.	0.6	10
104	The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine. <i>Anti-Cancer Drugs</i> , 2002, 13, 177-179.	0.7	13